GlassScriptPhysician profile
Khalid I Khan
NPI 1851475669
$12,196.19
in general payments reported to CMS, 2019-2025
34 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $479 · 2021: $1,090 · 2022: $1,442 · 2023: $2,305 · 2024: $5,373 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,182 · Food and Beverage: $3,316 · Travel and Lodging: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,181.67 |
| Food and Beverage | $3,316.18 |
| Travel and Lodging | $1,544.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,764.14 | 2023-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,271.33 | 2020-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,116.00 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $746.42 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.61 | 2019-2024 | Ofev, Jardiance, Spiriva Respimat |
| United Therapeutics Corporation | $316.46 | 2021-2024 | Tyvaso |
| Insmed, INC. | $280.38 | 2022-2025 | Arikayce |
| Mylan Specialty L.P. | $254.01 | 2021-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $226.18 | 2020-2025 | Verquvo, Winrevair, Belsomra |
| Verona Pharma, INC. | $178.07 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $174.16 | 2020-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $159.55 | 2022-2023 | Acthar |
| Amgen INC. | $126.41 | 2021-2025 | Tezspire, Repatha |
| Genzyme Corporation | $120.56 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $113.65 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $110.88 | 2022 | |
| Electromed, INC. | $93.12 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $80.46 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $72.34 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.78 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $40.96 | 2022-2025 | Opsynvi |
| Ethicon INC. | $38.65 | 2025 | Monarch Platform |
| Biosense Webster, INC. | $34.20 | 2022 | |
| Cvrx, INC. | $33.97 | 2024 | Barostim Neo System |
| Elutia, INC. | $31.90 | 2021 | |
| Eisai INC. | $29.05 | 2020 | |
| Apria Healthcare LLC | $28.68 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.72 | 2024 | Arcalyst |
| Baxter Healthcare | $21.93 | 2025 | Hillrom - Monarch Airway Clearance System |
| Inspire Medical Systems, INC. | $19.17 | 2023 | Inspire |
| Novo Nordisk INC | $16.86 | 2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $15.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.54 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.